Topics

Tocagen On The Rocks With Phase III Brain Cancer Study Failure

12:38 EDT 12 Sep 2019 | SCRIP

The firm’s stock crashed on news that its Toca 511/Toca FC regimen did not show an overall survival benefit or...

      

Related Stories

 

Original Article: Tocagen On The Rocks With Phase III Brain Cancer Study Failure

NEXT ARTICLE

More From BioPortfolio on "Tocagen On The Rocks With Phase III Brain Cancer Study Failure"

Quick Search